Search

Displaying results 1231 - 1240 of 7062 in total
  1. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]

    Synonyms: DL-ketamine
  2. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Products: Linagliptin 1A Pharma 5 mg - Filmtabletten
  3. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.

    Mixtures: ACETATO DE ALUMINIO, ACETATO DE ALUMINIO POLVOCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. … Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients.

  5. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous

  6. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]

  8. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

  9. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.

    Mixtures: Dologesic DF, Sinutab Sa Tab
  10. Drug

    Epirubicin

    go.drugbank.com/drugs/DB00445
    ApprovedInvestigational

    The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

    Categories: UGT2B7 Substrates with a Narrow Therapeutic IndexProducts: ALRUBIN® 50MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE